Revance Therapeutics, a clinical-stage biotech developing enhanced formulations of botulinum toxin (Botox), announced terms for its IPO on Monday. The Newark, CA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Revance Therapeutics would command a market value of $253 million.
Revance Therapeutics, which was founded in 1999, plans to list on the NASDAQ under the symbol RVNC. Revance Therapeutics initially filed confidentially on April 19, 2013. Cowen & Company and Piper Jaffray are the joint bookrunners on the deal.
